CN111670185A - 减少尿sCD163的C5aR抑制剂 - Google Patents

减少尿sCD163的C5aR抑制剂 Download PDF

Info

Publication number
CN111670185A
CN111670185A CN201880070265.5A CN201880070265A CN111670185A CN 111670185 A CN111670185 A CN 111670185A CN 201880070265 A CN201880070265 A CN 201880070265A CN 111670185 A CN111670185 A CN 111670185A
Authority
CN
China
Prior art keywords
individual
c5ar
treatment
antagonist
scd163
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880070265.5A
Other languages
English (en)
Chinese (zh)
Inventor
邓军
T·J·沙尔
P·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CN111670185A publication Critical patent/CN111670185A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201880070265.5A 2017-10-31 2018-10-30 减少尿sCD163的C5aR抑制剂 Pending CN111670185A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579716P 2017-10-31 2017-10-31
US62/579,716 2017-10-31
PCT/US2018/058134 WO2019089534A1 (en) 2017-10-31 2018-10-30 C5aR INHIBITOR REDUCTION OF URINARY sCD163

Publications (1)

Publication Number Publication Date
CN111670185A true CN111670185A (zh) 2020-09-15

Family

ID=66326509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070265.5A Pending CN111670185A (zh) 2017-10-31 2018-10-30 减少尿sCD163的C5aR抑制剂

Country Status (9)

Country Link
US (2) US20190134020A1 (https=)
EP (2) EP4671767A3 (https=)
JP (2) JP7789483B2 (https=)
KR (1) KR20200109297A (https=)
CN (1) CN111670185A (https=)
AR (1) AR113815A1 (https=)
AU (2) AU2018359237A1 (https=)
CA (1) CA3078732A1 (https=)
WO (1) WO2019089534A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801519A4 (en) 2018-06-07 2022-03-30 ChemoCentryx, Inc. DOSAGE AND EFFECTS OF C5A ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
SMT202400521T1 (it) 2018-11-30 2025-01-14 Chemocentryx Inc Formulazioni di capsula
CA3235574A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
CN114641288A (zh) 2019-11-08 2022-06-17 凯莫森特里克斯股份有限公司 补体成分C5a受体的无定形形式
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022093971A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
EP4262800A4 (en) * 2020-12-21 2024-11-20 ChemoCentryx, Inc. TREATMENT OF C3 GLOMERULOPATHY WITH A C5A INHIBITOR
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2016166357A2 (en) * 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
US20170283446A1 (en) * 2016-04-04 2017-10-05 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
PT2585064T (pt) * 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
NZ730123A (en) 2014-09-29 2023-05-26 Chemocentryx Inc Processes and intermediates in the preparation of c5ar antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2016166357A2 (en) * 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
US20170283446A1 (en) * 2016-04-04 2017-10-05 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID R.W. JAYNE,等: "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis", 《J AM SOC NEPHROL》 *
M NAGAI1,等: "Serum levels of the soluble haemoglobin scavenger receptor CD163 in MPO-ANCA associated renal vasculitis", 《SCANDINAVIAN JOURNAL OF RHEUMATOLOGY》 *
MEGHAN E. FREE，等: "The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis", 《J AM SOC NEPHROL》 *
VINCENT P. O’REILLY,等: "The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis", 《JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法

Also Published As

Publication number Publication date
EP4671767A2 (en) 2025-12-31
CA3078732A1 (en) 2019-05-09
JP2021501159A (ja) 2021-01-14
JP7789483B2 (ja) 2025-12-22
KR20200109297A (ko) 2020-09-22
US20230105869A1 (en) 2023-04-06
AR113815A1 (es) 2020-06-17
EP4671767A3 (en) 2026-03-11
EP3704110A1 (en) 2020-09-09
AU2024202593A1 (en) 2024-05-09
JP2023133317A (ja) 2023-09-22
WO2019089534A1 (en) 2019-05-09
AU2018359237A1 (en) 2020-04-30
EP3704110A4 (en) 2021-08-04
US20190134020A1 (en) 2019-05-09
TW201922289A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
CN111670185A (zh) 减少尿sCD163的C5aR抑制剂
Goldstein et al. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development
US20250326711A1 (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
CN108601790B (zh) C3肾小球病的治疗方法
EP1626721B1 (en) Carbostyril derivatives and mood stabilizers for treating mood disorders
AU2024323620A1 (en) Crystalline forms of a pi3k inhibitor and uses of same
WO2023220404A1 (en) Treatment of non-alcoholic steatohepatitis
KR20170095302A (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
JP2024133636A (ja) 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
JP2001508759A (ja) 片頭痛の処置法
EP1235572A2 (en) Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
CN111556750A (zh) 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
TWI913215B (zh) 減少尿液sCD163之C5aR抑制劑
EP1740176A2 (en) Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
US20020193374A1 (en) Reagents and methods for the diagnosis of CMV dissemination
CA3117563C (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
RU2772693C1 (ru) Твердые дисперсии и фармацевтические композиции, включающие замещенный индан, и способы их приготовления и применения
CZ2003234A3 (cs) 2-Aryl-8-oxodihydropurinové deriváty jako léčivo
HK40122597A (zh) 用於治疗纤维化的磷酸甘油酸脱氢酶抑制剂
EP3183229A1 (en) Apoe4-targeted theraputics that increase sirt1
HK1116664A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
AU2004200272A1 (en) Imidazoline Receptor binding compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination